Table 3 Elimination of colorectal CSCs based on bispecific antibodies
Targets | Drugs | Clinical trial title | References |
|---|---|---|---|
EpCAM × CD3 | MT110 | Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer (MT110-101) (ID: NCT00635596) | [237] |
EpCAM × CD3 | Catumaxomab | Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group (ID: NCT00836654) | [241] |
DLL4 × VEGF | Dilpacimab (ABT-165) | A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab (ID: NCT03368859) | [244] |
DLL4 × VEGF | CTX-009 (ABL001) | This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001 (ID: NCT03292783) | [246] |
DLL4 × VEGF | CTX-009 (ABL001) | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (ID: NCT05513742) | [247] |
EGFR × LGR5 | MCLA-158 | Inhibiting the growth of CRC organoids Efficacy in both Ras wild-type and Ras mutant PDX mice | [250] |
Targets | Drugs | Action | References |
|---|---|---|---|
EGFR × LGR5 | MCLA-158 | Inhibiting the growth of CRC organoids Efficacy in both Ras wild-type and Ras mutant PDX mice | [250] |